• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Annual Changes to the Nasdaq-100 Index®

    12/13/24 8:00:00 PM ET
    $AXON
    $ILMN
    $MRNA
    $MSTR
    Ordnance And Accessories
    Industrials
    Medical Specialities
    Health Care
    Get the next $AXON alert in real time by email

    NEW YORK, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX), which will become effective prior to market open on Monday, December 23, 2024.

    The following three companies will be added to the Index: Palantir Technologies Inc. (NASDAQ:PLTR), MicroStrategy Incorporated (NASDAQ:MSTR), and Axon Enterprise, Inc. (NASDAQ:AXON).

    The Nasdaq-100 Index® is composed of 100 of the largest non-financial companies1 listed on The Nasdaq Stock Market® and dates to January 1985 – nearly 40 years ago –when it was launched along with the Nasdaq Financial-100™ Index, which is comprised of 100 of the largest financial stocks on Nasdaq® These indexes act as benchmarks for financial products such as options, futures, and funds. The Nasdaq-100® is reconstituted each year in December, timed to coincide with the quadruple witch expiration Friday of the quarter.

    The Nasdaq-100 Index® is the basis of the Invesco QQQ Trust (NASDAQ:QQQ) which aims to provide investment results that, before expenses, correspond with the Nasdaq-100 Index® performance. In addition, options, futures and structured products based on the Nasdaq-100 Index® and the Invesco QQQ Trust trade on various exchanges.

    As a result of the reconstitution, the following three companies will be removed from the Index: Illumina, Inc. (NASDAQ:ILMN), Super Micro Computer, Inc. (NASDAQ:SMCI), and Moderna, Inc. (NASDAQ:MRNA).

    Information

    For information about the three companies to be added to the Nasdaq-100 Index®, please visit the following respective company websites:

    Palantir Technologies Inc. – https://www.palantir.com/

    MicroStrategy Incorporated – https://www.microstrategy.com/

    Axon Enterprise, Inc. – https://www.axon.com/

    About Nasdaq Global Indexes

    Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse. We continuously offer new opportunities for financial product sponsors across a wide spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index, and design solutions to financial organizations worldwide.

    _______________

    1 As outlined in the Nasdaq-100 Index® Methodology

    About Nasdaq

    Nasdaq (NASDAQ:NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X, or at www.nasdaq.com. 

    The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The Nasdaq OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq's proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

    - NDAQG - 

    Media Relations Contact Investor Relations Contact 
    Name: Jennifer Lawson

    Email: [email protected]

     Name: Index Client Services

    Email: [email protected]

     
        


    Primary Logo

    Get the next $AXON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXON
    $ILMN
    $MRNA
    $MSTR

    CompanyDatePrice TargetRatingAnalyst
    Super Micro Computer Inc.
    $SMCI
    5/7/2025$39.00Buy
    Needham
    MicroStrategy Incorporated
    $MSTR
    4/29/2025$480.00Buy
    H.C. Wainwright
    Super Micro Computer Inc.
    $SMCI
    4/25/2025$39.00Neutral
    Citigroup
    Nasdaq Inc.
    $NDAQ
    4/17/2025$91.00Neutral → Buy
    Redburn Atlantic
    Nasdaq Inc.
    $NDAQ
    4/8/2025$74.00Overweight → Equal-Weight
    Morgan Stanley
    Palantir Technologies Inc.
    $PLTR
    4/1/2025$90.00Neutral
    Daiwa Securities
    MicroStrategy Incorporated
    $MSTR
    4/1/2025$220.00Neutral → Sell
    Monness Crespi & Hardt
    Super Micro Computer Inc.
    $SMCI
    3/24/2025$40.00 → $32.00Neutral → Sell
    Goldman
    More analyst ratings

    $AXON
    $ILMN
    $MRNA
    $MSTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis

      New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO, May 29, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ:ILMN) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study published today in Science illustrates how this deep learning technology discovered regulatory variants in noncoding "promoter" segments that contribute up to 6% of the genetic causes of rare diseases. By turning data into insights, this technology is expected to help researchers accelerate new breakthroughs in diag

      5/29/25 2:01:00 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Nasdaq Executives to Present at Upcoming Investor Conferences

      NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) will be presenting at the following conferences in June with webcasts available at Nasdaq's Investor Relations website: ir.nasdaq.com/events.cfm. Who:Adena Friedman, Chair and CEO, NasdaqWhat:Piper Sandler Global Exchange & Trading ConferenceWhen:Thursday, June 5, 20252:30 PM ET  Who:Tal Cohen, President, NasdaqWhat:Morgan Stanley US Financials ConferenceWhen:Tuesday, June 10, 20259:45 AM ET   About Nasdaq Nasdaq (NASDAQ:NDAQ) is a global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financ

      5/28/25 4:05:00 PM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance
    • Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies

      Following FDA approval last year, Illumina's TSO Comprehensive test gains broad payer reimbursement, expanding access to comprehensive genomic profiling to match patients with targeted therapies Illumina's IVD portfolio will also expand to offer Pillar oncoReveal® CDx, the newest panel to deliver critical companion diagnostic testing using the Illumina MiSeq™ Dx System SAN DIEGO, May 28, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ:ILMN) today announced an expanded clinical oncology portfolio, unlocking the next new solutions to advance precision oncology and improve the standard of care. The company's broad range of clinical offerings will accelerate access to precision oncology for more pat

      5/28/25 9:15:00 AM ET
      $ILMN
      Medical Specialities
      Health Care

    $AXON
    $ILMN
    $MRNA
    $MSTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Mock James M converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 4% to 16,191 units (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      5/29/25 5:16:01 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Legal Officer Klinger Shannon Thyme converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 2% to 26,180 units (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      5/29/25 5:13:23 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Patten Jarrod M sold $241,300 worth of shares (650 units at $371.23), bought $1,013,780 worth of Series A Perpetual Strife Preferred Stock (10,000 units at $101.38) and exercised 1,700 shares at a strike of $17.60, decreasing direct ownership by 52% to 10,000 units (SEC Form 4)

      4 - MICROSTRATEGY Inc (0001050446) (Issuer)

      5/29/25 5:10:57 PM ET
      $MSTR
      Computer Software: Prepackaged Software
      Technology

    $AXON
    $ILMN
    $MRNA
    $MSTR
    Financials

    Live finance-specific insights

    See more
    • Defiance ETFs Announces First Weekly Distribution of $0.3350/Share for $MST: Defiance Leveraged Long + Income MSTR ETF

      MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs is pleased to announce the first weekly distribution for the Defiance Leveraged Long + Income MSTR ETF ($MST), the first leveraged MicroStrategy ETF designed to provide amplified exposure to MicroStrategy Incorporated (NASDAQ:MSTR) alongside consistent weekly income through an options-driven strategy. 05-20-2025 $MST Distribution Details - Ex & Record Date: 05/21/2025 - Payable Date: 05/22/2025 - $MST distribution: $0.3350/share- Estimated Return of Capital as of 5/22/25: 99.29%. As of 04/30/2025, the 30-Day SEC Yield for $MST is --.--%. Why $MST? - Leveraged Exposure: $MST seeks to deliver approximately 150% to 200% of MicroStrateg

      5/20/25 12:01:00 AM ET
      $MSTR
      Computer Software: Prepackaged Software
      Technology
    • Illumina Reports Financial Results for First Quarter of Fiscal Year 2025

      Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis)GAAP operating margin of 15.8% and non-GAAP operating margin of 20.4% for Q1 2025GAAP diluted EPS of $0.82 and non-GAAP diluted EPS of $0.97 for Q1 2025Cash provided by operations of $240 million and free cash flow of $208 million for Q1 2025For fiscal year 2025, we expect:Core Illumina revenue to decline between (1%) and (3%) on a constant currency basis year over year, down from low single digit growth previouslyRevenue outside of the Greater China region expected to grow between 0% and 2% in 2025 on a constant currency basis year over year and includes our estimate reflecting change

      5/8/25 4:13:00 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Axon reports Q1 2025 revenue of $604 million, up 31% year over year

      SCOTTSDALE, Ariz., May 7, 2025 /PRNewswire/ -- Software & Services revenue grows 39% to $263 millionAnnual recurring revenue grows 34% to $1.1 billionNet income of $88 million supports non-GAAP net income of $115 million and Adjusted EBITDA of $155 millionRaises full year revenue outlook to a range of $2.60 billion to $2.70 billion, up from $2.55 billion to $2.65 billion Fellow shareholders, Axon delivered a strong start to 2025, achieving record quarterly revenue while maintaining healthy margins and reinforcing our foundation for long-term growth through continued product in

      5/7/25 4:01:00 PM ET
      $AXON
      Ordnance And Accessories
      Industrials

    $AXON
    $ILMN
    $MRNA
    $MSTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham resumed coverage on Super Micro Computer with a new price target

      Needham resumed coverage of Super Micro Computer with a rating of Buy and set a new price target of $39.00

      5/7/25 8:38:19 AM ET
      $SMCI
      Computer Manufacturing
      Technology
    • H.C. Wainwright initiated coverage on MicroStrategy d/b/a Strategy with a new price target

      H.C. Wainwright initiated coverage of MicroStrategy d/b/a Strategy with a rating of Buy and set a new price target of $480.00

      4/29/25 8:12:45 AM ET
      $MSTR
      Computer Software: Prepackaged Software
      Technology
    • Citigroup initiated coverage on Super Micro Computer with a new price target

      Citigroup initiated coverage of Super Micro Computer with a rating of Neutral and set a new price target of $39.00

      4/25/25 8:33:41 AM ET
      $SMCI
      Computer Manufacturing
      Technology

    $AXON
    $ILMN
    $MRNA
    $MSTR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

      For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

      11/30/20 5:12:14 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXON
    $ILMN
    $MRNA
    $MSTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Illumina Inc.

      SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

      12/6/24 10:11:24 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Illumina Inc.

      SC 13G - ILLUMINA, INC. (0001110803) (Subject)

      12/5/24 7:27:01 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by MicroStrategy Incorporated

      SC 13G - MICROSTRATEGY Inc (0001050446) (Subject)

      11/14/24 6:24:12 PM ET
      $MSTR
      Computer Software: Prepackaged Software
      Technology

    $AXON
    $ILMN
    $MRNA
    $MSTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $AXON
    $ILMN
    $MRNA
    $MSTR
    SEC Filings

    See more
    • Director Patten Jarrod M sold $241,300 worth of shares (650 units at $371.23), bought $1,013,780 worth of Series A Perpetual Strife Preferred Stock (10,000 units at $101.38) and exercised 1,700 shares at a strike of $17.60, decreasing direct ownership by 52% to 10,000 units (SEC Form 4)

      4 - MICROSTRATEGY Inc (0001050446) (Issuer)

      5/29/25 5:10:57 PM ET
      $MSTR
      Computer Software: Prepackaged Software
      Technology
    • SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      5/14/25 4:20:13 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Chief Executive Officer Thaysen Jacob bought $998,674 worth of shares (12,350 units at $80.86), increasing direct ownership by 17% to 83,390 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      5/14/25 4:18:28 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • SEC Form SD filed by Axon Enterprise Inc.

      SD - AXON ENTERPRISE, INC. (0001069183) (Filer)

      5/29/25 3:43:38 PM ET
      $AXON
      Ordnance And Accessories
      Industrials
    • SEC Form DEFA14A filed by Nasdaq Inc.

      DEFA14A - NASDAQ, INC. (0001120193) (Filer)

      5/28/25 4:10:54 PM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form SD filed by Super Micro Computer Inc.

      SD - Super Micro Computer, Inc. (0001375365) (Filer)

      5/28/25 4:06:09 PM ET
      $SMCI
      Computer Manufacturing
      Technology

    $AXON
    $ILMN
    $MRNA
    $MSTR
    Leadership Updates

    Live Leadership Updates

    See more
    • Ted Myles Joins Cellarity as Chief Executive Officer

      Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

      5/12/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Shopify Inc to Join the Nasdaq-100 Index® Beginning May 19, 2025

      NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Shopify Inc. (NASDAQ:SHOP), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX®) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, May 19, 2025. Shopify Inc. will replace MongoDB, Inc. (NASDAQ:MDB) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted™ Index. MongoDB, Inc. will also be removed from the Nasdaq-100 Tech Sector™ Index (NASDAQ:NDXT), the Nasdaq-100 Technology Sector Market-Cap Weighted™ Index (NDXTMC™), the Nasdaq-100 Technology Sector Adjusted Market-Cap Weighted™ Index (NDXT10™), the Nasdaq-100 ESG™ Index (NASDAQ:NDXESG), the Nasdaq-100

      5/9/25 8:00:00 PM ET
      $MDB
      $NDAQ
      $SHOP
      Computer Software: Prepackaged Software
      Technology
      Investment Bankers/Brokers/Service
      Finance
    • Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec

      4/29/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)